- Offerings
- About Us
- Diagnostics
REFER TO THE OPERATIONS MANUAL OR USER GUIDE FOR WARNINGS, PRECAUTIONS AND LIMITATIONS FOR PROPER USE OF THE INSTRUMENT.
Assay technology | Chemiluminescent immunoassay |
Sample Types | Serum, Plasma |
Assay channels | 4 or 6 (Channels are configured for specific assays during installation by an Abbott representative.) |
Sample racks | 28 positions per rack Maximum 10 racks* |
Reaction trays | 16 reaction cells per tray Maximum loading: 27 trays per tray loader* |
Sample dispense volume |
50-100 μL ± 10% |
System control center |
VGA-compatible color monitor with keyboard |
Dimensions (HxWxD) |
68” x 91.6” x 33.1” 1.73 x 2.33 x .84 m |
Weight | 1660 lb 753 kg |
Uninterruptible power supply |
Single phase 200-240 VAC ± 10% |
Intended Use
The ABBOTT PRISMnEXT is an automated immunoassay analyzer designed to perform Chemiluminescent Immunoassay (ChLIA) technology. The ABBOTT PRISMnEXT performs batch/continuous access and STAT processing of specimens containing both large and small molecular weight analytes.
Usage and Safety Information
System operators must be aware of both biohazardous risks and risks inherent in operating electromechanical equipment and are responsible for using the system only as designed. Failure to follow safe use instructions could cause injury to the operator, damage to the system, or adversely affect assay results.
|
For In Vitro Diagnostic Use Only
Caution: United States Federal Law restricts these devices to sale and distribution by or on the order of a physician, or to a clinical laboratory; and use is restricted to, by, or on the order of a physician. These products contain human-sourced and/or potentially infectious components and must be handled in accordance with the OSHA Standard on Bloodborne Pathogens.
For complete assay information, see the assay specific package insert.
Intended Use: The ABBOTT PRISM Chagas assay is an in vitro chemiluminescent immunoassay (ChLIA) for the qualitative detection of antibodies to Trypanosoma cruzi (T cruzi), the causative agent of Chagas disease, in human serum and plasma specimens. The ABBOTT PRISM Chagas assay is intended to screen individual human donors, including volunteer donors of whole blood and blood components and other living donors, for the presence of antibodies to T cruzi. The assay is also intended for use in testing serum and plasma specimens to screen organ donors when specimens are obtained while the donor’s heart is still beating, and in testing blood specimens to screen cadaveric (non–heart-beating) donors. It is not intended for use on cord blood specimens.
Important Safety Information: Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in the package insert. The performance characteristics of this product have not been established for the laboratory diagnosis of T cruzi infection.
Intended Use: The ABBOTT PRISM HIV O Plus assay is an in vitro chemiluminescent immunoassay (ChLIA) for the qualitative detection of antibodies to HIV-1 (anti-HIV-1) Groups M and O and/or antibodies to HIV-2 (anti-HIV-2) in human serum and plasma specimens. The ABBOTT PRISM HIV O Plus assay is intended to screen individual human donors, including volunteer donors of Whole Blood and blood components and other living donors, for the presence of anti-HIV-1 Groups M and O and/or anti-HIV-2. The assay is also intended for use in testing blood and plasma specimens to screen organ donors when specimens are obtained while the donor’s heart is still beating, in testing blood specimens to screen cadaveric (non–heart-beating) donors, and as an aid in the diagnosis of HIV-1/HIV-2 infection. It is not intended for use in testing cord blood specimens.
Important Safety Information: Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in the package insert. This product contains sodium azide. Contact with acids liberates very toxic gas. This material and its container must be disposed of in a safe way.
Intended Use: The ABBOTT PRISM HBcore assay is an in vitro chemiluminescent immunoassay (ChLIA) for the qualitative detection of total antibody to hepatitis B core antigen (anti-HBc) in human serum and plasma specimens. The product is intended to screen individual human donors, including volunteer donors of whole blood and blood components, and other living donors to prevent transmission of hepatitis B virus (HBV) from such donors. It is also intended for use in testing blood and plasma specimens to screen organ donors when specimens are obtained while the donor's heart is still beating. It is not intended for use on cord blood specimens.
Important Safety Information: Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in the package insert. The performance characteristics of this product have not been established for the laboratory diagnosis of HBV infection. This product contains sodium azide. Contact with acids liberates very toxic gas. This material and its container must be disposed of in a safe wa.
Intended Use: The ABBOTT PRISM HBsAg assay is an in vitro chemiluminescent immunoassay (ChLIA) for the qualitative detection of hepatitis B surface antigen (HBsAg) in human serum and plasma specimens. The ABBOTT PRISM HBsAg (ChLIA) is intended to screen individual human donors, including volunteer donors of whole blood and blood components, and other living donors for the presence of HBsAg. It is also intended for use in testing blood and plasma specimens to screen organ donors when specimens are obtained while the donor’s heart is still beating, and in testing blood specimens to screen cadaveric (non-heart-beating) donors. It is not intended for use on cord blood specimens.
Important Safety Information: Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in the package insert. The performance characteristics of this product have not been established for the laboratory diagnosis of HBV infection. This product contains sodium azide. Contact with acids liberates very toxic gas. This material and its container must be disposed of in a safe way.
Intended Use: The ABBOTT PRISM HBsAg Confirmatory assay is an in vitro qualitative chemiluminescent immunoassay (ChLIA) used to confirm the presence of hepatitis B surface antigen (HBsAg) in human serum and plasma by means of specific antibody neutralization. The ABBOTT PRISM HBsAg Confirmatory assay is intended to be used for confirmation of samples found to be repeatedly reactive by the ABBOTT PRISM HBsAg assay.
Important Safety Information: Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in the package insert. The performance characteristics of this product have not been established for the laboratory diagnosis of HBV infection. This product contains sodium azide. Contact with acids liberates very toxic gas. This material and its container must be disposed of in a safe way.
Intended Use: The ABBOTT PRISM HCV assay is an in vitro chemiluminescent immunoassay (ChLIA) for the qualitative detection of antibodies to hepatitis C virus (anti‑HCV) in human serum and plasma specimens. The ABBOTT PRISM HCV (ChLIA) is intended to screen individual human donors, including volunteer donors of whole blood and blood components, and other living donors for the presence of anti-HCV. It is also intended for use in testing blood and plasma specimens to screen organ donors when specimens are obtained while the donor's heart is still beating, and in testing blood specimens to screen cadaveric (non-heart beating) donors. It is not intended for use on cord blood specimens.
Important Safety Information: Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in the package insert. The performance characteristics of this product have not been established for the laboratory diagnosis of HCV infection. This product contains sodium azide. Contact with acids liberates very toxic gas. This material and its container must be disposed of in a safe way.
Intended Use: The ABBOTT PRISM HTLV‑I/HTLV‑II assay is an in vitro chemiluminescent immunoassay (ChLIA) for the qualitative detection of antibodies to human T‑lymphotropic virus Type I and/or human T‑lymphotropic virus Type II (anti‑HTLV‑I/HTLV‑II) in human serum and plasma specimens. The ABBOTT PRISM HTLV-I/HTLV-II (ChLIA) is intended to screen individual human donors, including volunteer donors of whole blood and blood components, and other living donors for the presence of anti-HTLV-I/HTLV-II. It is also intended for use in testing blood and plasma specimens to screen organ donors when specimens are obtained while the donor’s heart is still beating. It is not intended for use on cord blood specimens.
Important Safety Information: Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in the package insert. The performance characteristics of this product have not been established for the laboratory diagnosis of HTLV-I/HTLV-II infection. This product contains sodium azide. Contact with acids liberates very toxic gas. This material and its container must be disposed of in a safe way.
|
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.